<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003091</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065795</org_study_id>
    <secondary_id>CBRG-9509</secondary_id>
    <secondary_id>NBSG-9509</secondary_id>
    <secondary_id>NCI-V97-1346</secondary_id>
    <nct_id>NCT00003091</nct_id>
  </id_info>
  <brief_title>High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma</brief_title>
  <official_title>Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Biotherapy Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may&#xD;
      stimulate a person's white blood cells to kill kidney cancer or melanoma cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of high-dose interferon alfa and&#xD;
      interleukin-2 in treating patients with metastatic kidney cancer or melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety, efficacy, and antitumor activity of high dose interferon&#xD;
      alfa-2b and interleukin-2 in patients with metastatic renal cell carcinoma or melanoma. II.&#xD;
      Determine the toxic effects of interferon alfa-2b and interleukin-2 in these patients.&#xD;
&#xD;
      OUTLINE: This is an open label study. Patients receive subcutaneous interferon alfa-2b on&#xD;
      days 1-4. Patients are hospitalized and receive bolus infusions of interleukin-2 (IL-2)&#xD;
      followed by a continuous infusion on days 5-7. Patients are observed at least 12 hours&#xD;
      following IL-2 treatment. Treatment is repeated every 4 weeks until disease progression or up&#xD;
      to a maximum of six cycles. Patients are followed every 2 months for one year, then for&#xD;
      survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: If at least 1 response is seen in the first 14 patients in each group, a&#xD;
      maximum of 40 patients per group will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <completion_date type="Actual">January 2000</completion_date>
  <primary_completion_date type="Actual">January 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven metastatic renal cell carcinoma or melanoma&#xD;
        Measurable or evaluable disease No active brain metastases Previously treated CNS&#xD;
        metastases responding to therapy are eligible, but CNS cannot be the site of evaluable&#xD;
        disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy: Not&#xD;
        specified Hematopoietic: Hematocrit at least 25 WBC at least 3,000/mm3 Platelet count at&#xD;
        least 100,000/mm3 PT and PTT within normal limits Hepatic: Bilirubin less than 2.0 mg/dL&#xD;
        Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No myocardial infarction within 6&#xD;
        months No medication for congestive heart failure or cardiac arrhythmias No hypertension&#xD;
        (unless blood pressure is stable off medication) Pulmonary: Must have reasonable&#xD;
        respiratory reserves and not require supplemental oxygen No dyspnea at rest Oxygen&#xD;
        saturation must be greater than 90% for patients with risk of respiratory symptoms Other:&#xD;
        Not HIV positive Not positive for hepatitis B antigen No chronic underlying&#xD;
        immunodeficiency No concurrent active infection requiring antibiotic therapy Not pregnant&#xD;
        or nursing No concurrent serious illness No family history of malignant hyperthermia No&#xD;
        hypersensitivity to interferon alfa-2b and interleukin-2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interleukin-2 and interferon alfa-2b&#xD;
        in combination therapy Chemotherapy: No prior systemic chemotherapy within 4 weeks of study&#xD;
        and recovered Endocrine therapy: No concurrent corticosteroid therapy Radiotherapy: No&#xD;
        prior radiotherapy within 4 weeks of interleukin-2 therapy No prior stereotactic&#xD;
        radiosurgery or gamma knife therapy within 1 week of interleukin-2 therapy Surgery: No&#xD;
        prior organ allograft transplantation Must be recovered from prior surgery Other: No&#xD;
        concurrent cyclosporin therapy No concurrent treatment with other anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Dillman, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Biotherapy Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloomington Hospital</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Center - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Regional Cancer Center</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09. Cancer Biother Radiopharm. 2006 Apr;21(2):130-7. doi: 10.1089/cbr.2006.21.130.</citation>
    <PMID>16706633</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2004</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert O. Dillman, MD</name_title>
    <organization>Hoag Memorial Hospital Presbyterian</organization>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

